IS Pharma (LON:ISPH) snaps up the rights to Episil
The Group has announced the acquisition for 1.75 million and royalties of the exclusive rights for Episil, an oncology supportive care product developed by Camurus AB (‘Camurus’), a privately owned Swedish life science company.
Episil is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment. Episil creates a strongly bioadhesive FluidCrystal® film that protects sensitive and…
Previous article Next article